[{"id":"4827359c-749f-4084-aeb0-6c8f0ce2d993","acronym":"dendritic cell","url":"https://clinicaltrials.gov/study/NCT07479667","created_at":"2026-03-28T01:39:16.862Z","updated_at":"2026-03-28T01:39:16.862Z","phase":"Phase 1","brief_title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","source_id_and_acronym":"NCT07479667 - dendritic cell","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" KRAS • TP53","pipe":"","alterations":" ","tags":["KRAS • TP53"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 02/05/2026","start_date":" 02/05/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2026-03-18"},{"id":"9f749ec0-9a4e-415b-87ef-80069ba67c42","acronym":"MA-CRC-II-018","url":"https://clinicaltrials.gov/study/NCT07478731","created_at":"2026-03-28T01:41:18.497Z","updated_at":"2026-03-28T01:41:18.497Z","phase":"Phase 2","brief_title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT07478731 - MA-CRC-II-018","lead_sponsor":"Hong Qiu","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/20/2025","start_date":" 12/20/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-17"},{"id":"09a0d183-0830-4536-98ee-15af8f5f5f0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474025","created_at":"2026-03-28T01:40:03.290Z","updated_at":"2026-03-28T01:40:03.290Z","phase":"","brief_title":"Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses","source_id_and_acronym":"NCT07474025","lead_sponsor":"Jules Bordet Institute","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2026-03-16"},{"id":"56ce6852-9361-474d-8838-60a89afe127e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475182","created_at":"2026-03-28T01:42:49.380Z","updated_at":"2026-03-28T01:42:49.380Z","phase":"Phase 1","brief_title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","source_id_and_acronym":"NCT07475182","lead_sponsor":"Hainan Cancer Hospital","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/06/2025","start_date":" 12/06/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 06/06/2028","study_completion_date":" 06/06/2028","last_update_posted":"2026-03-16"},{"id":"fd4f177e-f85d-440b-907a-20a6e87e3329","acronym":"PRO-ACTIVE","url":"https://clinicaltrials.gov/study/NCT07469709","created_at":"2026-03-28T01:44:12.315Z","updated_at":"2026-03-28T01:44:12.315Z","phase":"","brief_title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","source_id_and_acronym":"NCT07469709 - PRO-ACTIVE","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"55b1a0de-6575-4213-92f4-3ad23c6cc089","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150403","created_at":"2025-09-06T13:44:19.461Z","updated_at":"2025-09-06T13:44:19.461Z","phase":"Phase 2","brief_title":"A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150403","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-09-02"},{"id":"5896371c-1ef5-48dc-96cb-56888e31ddde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150247","created_at":"2025-09-06T13:44:15.174Z","updated_at":"2025-09-06T13:44:15.174Z","phase":"Phase 2","brief_title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150247","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-09-02"},{"id":"25644c79-5dff-4f90-909f-44d8053dcbb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07148128","created_at":"2025-08-30T13:47:31.239Z","updated_at":"2025-08-30T13:47:31.239Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","source_id_and_acronym":"NCT07148128","lead_sponsor":"Auricula Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-08-29"},{"id":"769c2f13-1a5f-40f3-a679-550e492e7f3c","acronym":"NeoART-M","url":"https://clinicaltrials.gov/study/NCT07095309","created_at":"2025-08-02T14:02:03.314Z","updated_at":"2025-08-02T14:02:03.314Z","phase":"Phase 2","brief_title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","source_id_and_acronym":"NCT07095309 - NeoART-M","lead_sponsor":"Metanoic Health Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 08/30/2032","primary_completion_date":" 08/30/2032","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2025-07-31"},{"id":"70cc1b41-3bca-4660-a674-24287764e8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT07094204","created_at":"2025-08-02T14:04:37.665Z","updated_at":"2025-08-02T14:04:37.665Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","source_id_and_acronym":"NCT07094204","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-07-30"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"e87af69a-d323-4381-8103-c49ab9c91458","acronym":"","url":"https://clinicaltrials.gov/study/NCT06934538","created_at":"2025-07-12T13:49:40.870Z","updated_at":"2025-07-12T13:49:40.870Z","phase":"Phase 1/2","brief_title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06934538","lead_sponsor":"Brenus Pharma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • cyclophosphamide • oxaliplatin • STC-1010"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-07-11"},{"id":"f3a57e99-36b8-4856-b1b8-be1b041c0803","acronym":"","url":"https://clinicaltrials.gov/study/NCT07048847","created_at":"2025-07-05T13:56:07.976Z","updated_at":"2025-07-05T13:56:07.976Z","phase":"","brief_title":"The Effect of Aerobic Exercise on Selective Biomarkers of Patients With Cancer","source_id_and_acronym":"NCT07048847","lead_sponsor":"Izmir Bakircay University","biomarkers":" LEP","pipe":"","alterations":" ","tags":["LEP"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/15/2023","primary_completion_date":" 08/15/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2025-07-03"},{"id":"09c97c25-8898-451b-b433-f40b31dafada","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044362","created_at":"2025-07-05T13:59:39.582Z","updated_at":"2025-07-05T13:59:39.582Z","phase":"","brief_title":"Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis","source_id_and_acronym":"NCT07044362","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-07-02"},{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"dacc9da3-7f50-4fcd-b6ab-f82afa578e33","acronym":"","url":"https://clinicaltrials.gov/study/NCT07025850","created_at":"2025-06-21T13:17:03.504Z","updated_at":"2025-06-21T13:17:03.504Z","phase":"Phase 1/2","brief_title":"Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT07025850","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-06-18"},{"id":"b0c3d0f3-340f-42f7-821e-d51795e6563a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020221","created_at":"2025-06-14T13:52:20.544Z","updated_at":"2025-06-14T13:52:20.544Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","source_id_and_acronym":"NCT07020221","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-06-13"},{"id":"9fb2cdde-012a-4d53-b589-d932fba3f768","acronym":"C2025-009-01","url":"https://clinicaltrials.gov/study/NCT07014878","created_at":"2025-06-14T13:55:09.580Z","updated_at":"2025-06-14T13:55:09.580Z","phase":"Phase 1","brief_title":"A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07014878 - C2025-009-01","lead_sponsor":"Beijing DCTY Biotech Co.,Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-11"},{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"5c7995c8-ead0-4dee-b97d-b534e2ba82a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07007689","created_at":"2025-06-07T14:23:15.486Z","updated_at":"2025-06-07T14:23:15.486Z","phase":"","brief_title":"A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer","source_id_and_acronym":"NCT07007689","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-06-06"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"ba38e7d6-cf30-459e-86ad-9dab62c47dd9","acronym":"FIRE-11","url":"https://clinicaltrials.gov/study/NCT07004413","created_at":"2025-06-07T14:43:38.689Z","updated_at":"2025-06-07T14:43:38.689Z","phase":"Phase 3","brief_title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","source_id_and_acronym":"NCT07004413 - FIRE-11","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" BRAF • CA 19-9","pipe":"","alterations":" ","tags":["BRAF • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-06-04"}]